Ciprofloxacin base pharma grade for oral and injectable manufacture is supplied as a nearly white to pale yellow crystalline powder with a melt at 255–258°C (decomposition) and molecular weight 331.34 g/mol. The molecule carries two ionizable centers that define downstream formulation strategy: the C-3 carboxylic acid (pKa₁ 6.09) and the C-7 piperazinyl nitrogen (pKa₂ 8.74). Finished-dose manufacturers verifying incoming API should require XRPD confirmation of the anhydrous crystalline form, particle size by laser diffraction (Malvern Mastersizer 3000, dry dispersion at 1.5 bar), residual solvents per USP <467>, elemental impurities per ICH Q3D, and loss on drying ≤0.5% w/w. A milled API with D₉₀ ≤75 μm is the practical default for immediate-release oral solids. D₉₀ ≤50 μm is specified for oral suspension grades to limit sedimentation velocity. For cross-market dossier support, the supplier should maintain an active ASMF or CEP and align impurity reporting with the Ph. Eur. ciprofloxacin monograph. The pH-dependent solubility profile directly routes each dosage form into a distinct processing pathway.

Why Does Direct Compression Fail at 71% w/w API Load in 500 mg Ciprofloxacin Tablets?

Unmilled ciprofloxacin base exhibits bulk density near 0.32 g/mL, tapped density near 0.45 g/mL, Carr index 29–35%, and Hausner ratio 1.35–1.45. These flow indices fall below the acceptance window for high-speed rotary compression. A 500 mg dose in a 700 mg core places the active at 71.4% w/w. Direct compression trials on a Korsch XL 400 at 60,000 tablets/h frequently generate weight variation RSD above 5% and capping at hardness above 8 kp; both failure modes are traced to poor powder flow and low packing density in the feed frame. Wet granulation is therefore the standard route. Dry binder PVP K30 added as a 5% w/v aqueous solution at 2–3% w/w dry solids is mixed with API, microcrystalline cellulose PH-102 (12–15% w/w), crospovidone CL-SF (3% w/w), and pregelatinized starch (8% w/w) in a high-shear granulator (GEA Collette GRAL 10). Impeller tip speed 2–4 m/s, chopper 1,500 rpm, and granulation time 3–6 min are set to bound granule growth; overgranulation shifts granule PSD toward size span above 2.0, which transfers directly into dissolution RSD at the 30-minute Q-time. The wet mass is dried in a fluid-bed dryer at inlet 60–70°C to product temperature 40–45°C; final LOD target is ≤2.0% w/w. Milling through a 20–40 mesh screen supplies compressible granules. Lubrication with magnesium stearate 1.0% w/w in a bin blender at 15 rpm for 3 min is kept short to avoid lubricant overcoating and dissolution slowdown. Compression force 10–20 kN yields tablet hardness 10–15 kp (98–147 N) and friability below 0.5% per USP <1216>. Film coating with Opadry II white at 2–3% weight gain in a perforated pan at inlet 65°C, exhaust 42°C, and pan speed 4–8 rpm produces the finished 500 mg IR tablet. Dissolution acceptance follows the USP Ciprofloxacin Tablets monograph: 900 mL of 0.01 N hydrochloric acid, Apparatus 2 at 50 rpm, Q=80% in 30 min with HPLC-UV detection at 278 nm. Moisture uptake at RH above 60% during granulation causes punch-face picking; granulation and compression suites are held at 40–50% RH for this reason.

Bilayer Matrix Geometry Controls 24-Hour Release Without Initial Dose Dumping

For the extended-release presentation, ciprofloxacin base is formed into a bilayer construct in which a rapid-release layer supplies a prompt rise to therapeutic plasma concentration and a swelling-controlled matrix layer provides near-constant release over 24 hours. The pH-dependent solubility of ciprofloxacin base creates the primary formulation risk: protonation of the piperazinyl nitrogen at gastric pH 1.2 increases solubility, and a poorly selected matrix can release a disproportionate fraction of dose in the first two hours. The generic ER approach uses hypromellose K4M (20–25% w/w of the release layer) combined with carbomer 971P (8–10% w/w) as a dual-swelling system. Carbomer hydration under gastric pH initially forms a low-viscosity gel; as the formulation moves to intestinal pH 6.8, ionization expands the carbomer network and raises gel viscosity, compensating for declining ciprofloxacin solubility. Matrix layer composition typically includes lactose monohydrate (10–15% w/w) as a release-channel former, talc (2% w/w), and magnesium stearate (1% w/w). The rapid-release layer comprises 100 mg of API with microcrystalline cellulose (20% w/w), croscarmellose sodium (5% w/w), and colloidal silicon dioxide (1% w/w). Bilayer compression on a Fette 3090i with pre-compression 8–10 kN and main compression 20–30 kN requires strict control of layer interface integrity; turret speed above 40,000 tablets/h can induce layer separation if granule densities differ by more than 15%. Multi-point release profiling follows USP <724> with pH-shift media; absolute Q-values are product-specific, and published data for the 500 mg generic bilayer configuration is limited. In-process controls include individual-layer weight RSD ≤2.0%, tablet hardness 12–18 kp, and 24-hour release tail RSD ≤5% across six tablets. The finished 500 mg ER tablet is not scoreable; splitting breaks the release-controlling surface and produces unpredictable dose flux in patients.

Roller compaction of ciprofloxacin base at 35–50 kN roll force on an Alexanderwerk WP 120 raises bulk density from 0.32 g/mL to 0.58 g/mL, bringing powder flow into the range required for automatic capsule filling. Uncompacted API shows rathole piping and auger jamming on dosator-type encapsulation machines above 40,000 capsules/h; batch-to-batch variation in crystallite aspect ratio from the API supplier further destabilizes fill weight. The capsule presentation uses 250 mg or 500 mg of ciprofloxacin base, preblended with microcrystalline cellulose PH-112 (20% w/w), pregelatinized starch (10% w/w), crospovidone CL-SF (3–5% w/w), colloidal silicon dioxide (0.5% w/w), and sodium stearyl fumarate (2% w/w) as a non-hydrophobic lubricant. The dry blend is compacted, milled through an 18–60 mesh screen, and filled into hard gelatin capsules on a Bosch GKF 1500 at 60,000–100,000 capsules/h. Size 00 shells accept the 250 mg fill weight; the 500 mg strength requires compacted granule bulk density ≥0.55 g/mL to remain inside the size 00 shell body, otherwise Size 000 equipment tooling is required. In-process weight verification every 15 minutes uses acceptance limits of ±5% individual and RSD ≤3%. Dissolution follows the IR tablet compendial condition with modified apparatus selection justified per ICH Q2(R1): 900 mL of 0.01 N HCl, USP Apparatus 1 at 100 rpm, Q=80% in 30 min. Storage of filled capsules at 25°C ± 2°C / 60% RH ± 5% RH is established from ICH Q1A(R2) stability protocols. Gelatin cross-linking can occur if granule LOD exceeds 2.0%; moisture-sensitive silica gel desiccant packets are therefore inserted in HDPE bottles at 2 g per 100 capsules.

Oral Granule Suspension Stability and Reconstituted Viscosity Control

In the oral suspension segment, a ciprofloxacin base grade milled to D₉₀ ≤50 μm is pre-granulated with sucrose before blending with suspending agents at 125 mg/5 mL and 250 mg/5 mL after reconstitution. The formulation per 5 mL contains ciprofloxacin base 250 mg (or 125 mg), sucrose 2,000 mg (40% w/v), sorbitol solution 70% at 500 mg, xanthan gum 15 mg (0.3% w/v), microcrystalline cellulose plus carmellose sodium (Avicel RC-591) 30 mg (0.6% w/v), methylparaben 7.5 mg (0.15% w/v), propylparaben 1.0 mg (0.02% w/v), and citric acid monohydrate to pH 4.5–5.5. API is pre-granulated with a portion of sucrose in a fluid-bed granulator (Glatt GPCG 3) at inlet 50–60°C, product temperature 35–40°C, and spray rate 10–15 g/min to LOD ≤2.0%; the dried granulate is milled through 20–40 mesh. Filling targets 100 mL amber HDPE bottles with 2 g silica gel desiccant and induction-sealed closures. Reconstitution with 80 mL purified water at 25°C followed by 30 s shaking and q.s. to 100 mL produces a suspension with Brookfield RV Spindle #2 at 50 rpm viscosity of 150–300 cP. Sedimentation volume after 24 h remains ≥0.9 with redispersion within 15 s. The suspension must not contain magnesium aluminum silicate or iron oxide colorants: ciprofloxacin base undergoes ionic complexation with divalent and trivalent cations, which reduces free drug concentration and alters bioavailability. Microbial limits follow USP <61> and USP <62>; reconstituted suspension hold time at 15–25°C is established by ICH Q1A(R2) stress studies and is typically 14 days.

Compliance test matrix for the four dosage forms generated from the same ciprofloxacin base API lot.

When Ciprofloxacin Base Is Converted In Situ to Lactate for Sterile Infusion

Because free-base ciprofloxacin is practically insoluble in water at physiological pH, injectable manufacture requires in-situ salt formation with 1.0 M lactic acid. Stoichiometric addition at a 1:1 molar ratio with ciprofloxacin base — approximately 54.4 mg lactic acid per 200 mg API by molecular weight calculation — converts the free base to the water-soluble lactate in a jacketed dissolution vessel at 20–25°C under nitrogen blanketing. The target pH window is 3.5–4.6; excursions above pH 5.0 risk localized precipitation of the unionized species. The 2 mg/mL ready-to-infuse solution is prepared by diluting the lactate concentrate into 5% dextrose monohydrate in water for injection; sodium hydroxide and additional lactic acid are used for final pH adjustment. Sterile filtration through a 0.22 μm PVDF membrane (Millipore Durapore GV) at differential pressure ≤1.0 bar precedes aseptic filling into flexible polyolefin bags. Terminal steam sterilization at 121°C for 15 min is generally avoided because ciprofloxacin lactate solutions at the upper pH boundary can undergo localized precipitation inside the autoclave during thermal equilibration. USP <71> sterility testing by membrane filtration and USP <85> bacterial endotoxin testing with acceptance limit ≤0.75 EU/mg are release tests. Infusion solutions are incompatible with lactated Ringer's injection and any parenteral containing Ca²⁺, Mg²⁺, or Al³⁺ due to fluoroquinolone chelation; this incompatibility is validated by visual precipitation assay and free-solution ICP-MS metal speciation. Photodegradation of the quinolone core under UV light mandates amber overwrap or carton storage; ICH Q1B photostability testing is part of the dossier. The finished 200 mg/100 mL and 400 mg/200 mL presentations carry pH 3.5–4.6 and osmolality 285–300 mOsm/kg.

At the 10 mg/mL concentrate strength, ciprofloxacin base is converted to lactate and filled aseptically into Type I borosilicate glass vials of 20 mL (200 mg) and 40 mL (400 mg) with bromobutyl rubber stoppers and aluminium flip-off seals; vial washing uses WFI with endotoxin limit ≤0.25 EU/mL and dry-heat depyrogenation in a tunnel oven at 300°C for more than 5 min. Fill volume control on the vial line is set at ±2.0% of nominal; in-process particulate monitoring follows USP <790> visual inspection after 100% automated inspection with knockdown rates typically under 0.5%. The concentrate presentation supports the higher intravenous dosing schedules required for inhalational anthrax and nosocomial pneumonia, where 400 mg is infused every 8 hours and the cumulative daily dose reaches 1,200 mg. For complicated urinary tract infection and pyelonephritis, 400 mg every 12 hours is the accepted adult schedule. Pediatric patients above 6 months receive weight-based dosing at 10 mg/kg every 8–12 hours, with dose-banding protocols used to reduce waste from partial vials. Aseptic compounding of diluted infusions in hospital settings follows USP <797> beyond-use limits; the diluted product in 0.9% NaCl or D5W at 1–2 mg/mL is stable for 14 days under refrigeration at 2–8°C with light protection, based on published stability data for the lactate salt in isotonic diluents. Reconstituted ciprofloxacin infusion must never be mixed in the same intravenous line with heparin, ampicillin/sulbactam, or amphotericin B without validation of line compatibility; published incompatibility data for ciprofloxacin with amphotericin B is attributed to pH excursion-driven precipitation.

Formulation composition ranges across non-sterile oral presentations derived from production-scale development batches.